These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 24613255)

  • 1. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
    Cserni G; Vörös A; Liepniece-Karele I; Bianchi S; Vezzosi V; Grabau D; Sapino A; Castellano I; Regitnig P; Foschini MP; Zolota V; Varga Z; Figueiredo P; Decker T; Focke C; Kulka J; Kaya H; Reiner-Concin A; Amendoeira I; Callagy G; Caffrey E; Wesseling J; Wells C
    Breast; 2014 Jun; 23(3):259-63. PubMed ID: 24613255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
    van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
    Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki67 Immunohistochemistry Quantification in Breast Carcinoma: A Comparison of Visual Estimation, Counting, and ImmunoRatio.
    van den Berg EJ; Duarte R; Dickens C; Joffe M; Mohanlal R
    Appl Immunohistochem Mol Morphol; 2021 Feb; 29(2):105-111. PubMed ID: 32590453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide images.
    Joseph J; Roudier MP; Narayanan PL; Augulis R; Ros VR; Pritchard A; Gerrard J; Laurinavicius A; Harrington EA; Barrett JC; Howat WJ
    Sci Rep; 2019 Sep; 9(1):12845. PubMed ID: 31492872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
    Jang MH; Kim HJ; Chung YR; Lee Y; Park SY
    PLoS One; 2017; 12(2):e0172031. PubMed ID: 28187177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.
    Plancoulaine B; Laurinaviciene A; Herlin P; Besusparis J; Meskauskas R; Baltrusaityte I; Iqbal Y; Laurinavicius A
    Virchows Arch; 2015 Oct; ():. PubMed ID: 26481244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience.
    Li W; Lu N; Chen C; Lu X
    J Int Med Res; 2023 Aug; 51(8):3000605231195468. PubMed ID: 37652458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Ki-67 Index in Patients With Endometrial Stromal Sarcoma.
    Meng Y; Quan Q; Zhang F; Liu Y; Ren S; Mu X
    Front Med (Lausanne); 2021; 8():823505. PubMed ID: 35145981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitizing Effect of Bromelain Using Tumor Mice Model via Ki-67 and PARP-1 Inhibition.
    Mekkawy MH; Fahmy HA; Nada AS; Ali OS
    Integr Cancer Ther; 2021; 20():15347354211060369. PubMed ID: 34825602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra-Tumor Heterogeneity Revealed by Mass Spectrometry Imaging Is Associated with the Prognosis of Breast Cancer.
    Gawin M; Kurczyk A; Niemiec J; Stanek-Widera A; Grela-Wojewoda A; Adamczyk A; Biskup-Frużyńska M; Polańska J; Widłak P
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The additional value of ONEST (Observers Needed to Evaluate Subjective Tests) in assessing reproducibility of oestrogen receptor, progesterone receptor, and Ki67 classification in breast cancer.
    Cserni B; Bori R; Csörgő E; Oláh-Németh O; Pancsa T; Sejben A; Sejben I; Vörös A; Zombori T; Nyári T; Cserni G
    Virchows Arch; 2021 Dec; 479(6):1101-1109. PubMed ID: 34415429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor.
    Jiang P; Jia M; Hu J; Huang Z; Deng Y; Lai L; Ding S; Hu Z
    Onco Targets Ther; 2020; 13():10841-10850. PubMed ID: 33149602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression.
    Tiede S; Kalathur RKR; Lüönd F; von Allmen L; Szczerba BM; Hess M; Vlajnic T; Müller B; Canales Murillo J; Aceto N; Christofori G
    Oncogene; 2021 Jan; 40(1):12-27. PubMed ID: 33046799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
    Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
    Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
    Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
    Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
    Stevanovic L; Choschzick M; Moskovszky L; Varga Z
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention.
    Kapinova A; Kubatka P; Golubnitschaja O; Kello M; Zubor P; Solar P; Pec M
    Environ Health Prev Med; 2018 Aug; 23(1):36. PubMed ID: 30092754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.
    Fantony JJ; Howard LE; Csizmadi I; Armstrong AJ; Lark AL; Galet C; Aronson WJ; Freedland SJ
    Biomark Med; 2018 Jul; 12(7):727-736. PubMed ID: 29902938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium.
    Cserni G
    Virchows Arch; 2018 Aug; 473(2):145-153. PubMed ID: 29594352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.